OnCo
News & evidence

Edge

The freshest signals in cancer: new papers, trial results, approvals and law, updated with every build.

This week in numbers

Items dated to a day in the last seven days, across every source; dates known only to the month or year are not counted.

Latest

RSSJSON

200 items on this page; 300 more in the feeds. Ranked newest first, with approvals, withdrawals and phase 3 results counting as two weeks fresher than their date, other results, law and papers in the leading journals one week fresher, and preprints one week older; every kind keeps its most recent items so no filter is empty while its source has data. Within a day the weightier items come first.

2

  1. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-22

    392 changelog entries, 1 regulatory event, 2 upcoming dates, 2 corrections.

  2. Paper· J Pediatr Endocrinol Metab

    Successful management of paediatric chronic SIAD with oral urea: report of two cases.

    Published in J Pediatr Endocrinol Metab on 22 September 2026; matched the OnCo record for Paediatric low-grade glioma.

    Paediatric low-grade glioma

13

  1. Paper· Blood Cancer Discov

    A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

    Published in Blood Cancer Discov on 21 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

    Acute lymphoblastic leukaemiaCD22
  2. Paper· Muscle Nerve

    Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy.

    Published in Muscle Nerve on 21 September 2026; matched the OnCo record for Small intestine cancer.

    Small intestine cancer
  3. Paper· Pediatr Blood Cancer

    Comparative Effectiveness of Antibiotic Prophylaxis Regimens in Pediatric Acute Myeloid Leukemia.

    Published in Pediatr Blood Cancer on 21 September 2026; matched the OnCo record for Acute myeloid leukaemia in children.

    Acute myeloid leukaemia in children
  4. Paper· Cancer Immunol Res

    IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

    Published in Cancer Immunol Res on 21 September 2026; matched the OnCo record for TCR-T cell therapy.

    TCR-T cell therapy
  5. Paper· Signal Transduct Target Ther

    Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.

    Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for Aumolertinib.

    Aumolertinib
  6. Paper· Genet Test Mol Biomarkers

    Integrative Genetic and Bioinformatic Analysis of Androgen Pathway Gene Polymorphisms, Testosterone, and PSA Levels in Prostate Cancer.

    Published in Genet Test Mol Biomarkers on 21 September 2026; matched the OnCo record for CYP17A1.

    CYP17A15-alpha-reductase type 2
  7. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-21

    310 changelog entries, 1 upcoming date, 7 publications, 2 corrections.

  8. Paper· Arthritis Care Res (Hoboken)

    Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

    Published in Arthritis Care Res (Hoboken) on 21 September 2026; matched the OnCo record for Tocilizumab.

    Tocilizumab
  9. Paper· Adv Sci (Weinh)

    Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy.

    Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for Floxuridine.

    Floxuridine
  10. Paper· Clin Cancer Res

    Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

    Published in Clin Cancer Res on 21 September 2026; matched the OnCo record for Adavosertib.

    AdavosertibCeralasertibWEE1
  11. Paper· Br J Dermatol

    Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

    Published in Br J Dermatol on 21 September 2026; matched the OnCo record for Mogamulizumab.

    Mogamulizumab
  12. Paper· Head Neck

    Toripalimab Plus TPF as Induction Chemoimmunotherapy for the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Prospective Phase II Study.

    Published in Head Neck on 21 September 2026; matched the OnCo record for Toripalimab.

    Toripalimab
  13. Paper· Arthritis Rheumatol

    Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

    Published in Arthritis Rheumatol on 21 September 2026; matched the OnCo record for Emapalumab.

    Emapalumab

13

  1. Paper· Lab Anim Res

    Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment.

    Published in Lab Anim Res on 20 September 2026; matched the OnCo record for Genetically engineered mouse models.

    Genetically engineered mouse models
  2. Paper· Oncogene

    Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research.

    Published in Oncogene on 20 September 2026; matched the OnCo record for Humanised mouse models.

    Humanised mouse models
  3. Paper· Cancer Causes Control

    Bridging the data latency gap: automated extraction of genomic biomarkers from unstructured clinical documents to support real-world oncology data.

    Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Oncotype DX.

    Oncotype DX
  4. Paper· Crit Rev Oncol Hematol

    Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

    Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Penile cancer.

    Penile cancer
  5. Paper· Crit Rev Oncol Hematol

    Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand? Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand?

    Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Belzutifan.

    Belzutifan
  6. Paper· Cardiovasc Toxicol

    Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.

    Published in Cardiovasc Toxicol on 20 September 2026; matched the OnCo record for HER4.

    HER4Strain echocardiography
  7. Paper· Br J Haematol

    Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

    Published in Br J Haematol on 20 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

    Acute lymphoblastic leukaemia
  8. Paper· Acta Biomater

    Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

    Published in Acta Biomater on 20 September 2026; matched the OnCo record for CD123.

    CD123
  9. Paper· Int J Cancer

    Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy-Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post-Treatment.

    Published in Int J Cancer on 20 September 2026; matched the OnCo record for CAPOX.

    CAPOX
  10. Paper· Cancer Causes Control

    Predictors of perceived value of multi-cancer early detection testing: a national PRECEDE-PROCEED framework study.

    Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Multi-cancer early detection.

    Multi-cancer early detection
  11. Paper· Expert Opin Ther Pat

    Progress with FAK inhibitors in the patent literature (2020-present).

    Published in Expert Opin Ther Pat on 20 September 2026; matched the OnCo record for Avutometinib + defactinib.

    Avutometinib + defactinib
  12. Paper· Future Oncol

    Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

    Published in Future Oncol on 20 September 2026; matched the OnCo record for Avelumab.

    Avelumab
  13. Paper· Clin Med (Lond)

    Updates to contemporary care of glioblastoma.

    Published in Clin Med (Lond) on 20 September 2026; matched the OnCo record for Tumour treating fields.

    Tumour treating fields

22

  1. Paper· Bioorg Chem

    A pyridone-fused imidazo[1,2-a]pyridine hybrid binds to tubulin at the vinblastine site, depolymerizes microtubules and inhibits Cancer cell proliferation.

    Published in Bioorg Chem on 19 September 2026; matched the OnCo record for Vinblastine.

    Vinblastine
  2. Paper· J Hematop

    Acute myeloid leukemia arising in treated chronic lymphocytic leukemia/small lymphocytic lymphoma: a challenge in analysis of lineage relationship.

    Published in J Hematop on 19 September 2026; matched the OnCo record for CD123.

    CD123
  3. Paper· Curr Opin Oncol

    Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers.

    Published in Curr Opin Oncol on 19 September 2026; matched the OnCo record for Talazoparib.

    TalazoparibWEE1
  4. Paper· EJHaem

    Clinicopathologic Characteristics of Somatic <i>TP53</i> Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.

    Published in EJHaem on 19 September 2026; matched the OnCo record for BCR::ABL1.

    BCR::ABL1
  5. Paper· Mol Ther

    Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

    Published in Mol Ther on 19 September 2026; matched the OnCo record for Plerixafor.

    Plerixafor
  6. Paper· BMJ Paediatr Open

    Distribution, socioeconomic inequalities and contributing factors of anaemia prevalence across wealth index among Indian adolescent girls: multivariate decomposition analysis of nationally representative survey.

    Published in BMJ Paediatr Open on 19 September 2026; matched the OnCo record for HB-200.

    HB-200
  7. Paper· Radiother Oncol

    Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study.

    Published in Radiother Oncol on 19 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.

    Limited-stage small-cell lung cancer
  8. Paper· Eur J Nucl Med Mol Imaging

    Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.

    Published in Eur J Nucl Med Mol Imaging on 19 September 2026; matched the OnCo record for Gallium-68 gozetotide.

    Gallium-68 gozetotide
  9. Paper· Int J Surg Pathol

    Hepatocellular Carcinoma With a Grade 3 Neuroendocrine Tumor Component: A Case Report.

    Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Grade 3 well-differentiated neuroendocrine tumour.

    Grade 3 well-differentiated neuroendocrine tumour
  10. Paper· Cell Death Discov

    Immunogenic cell death as a mechanism of synergy between sunitinib and <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

    Published in Cell Death Discov on 19 September 2026; matched the OnCo record for Lutetium-177 dotatate.

    Lutetium-177 dotatatePancreatic neuroendocrine tumours
  11. Paper· Biochem Pharmacol

    In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies.

    Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for In vivo CAR-T.

    In vivo CAR-T
  12. Paper· Libyan J Med

    Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

    Published in Libyan J Med on 19 September 2026; matched the OnCo record for Anal high-grade squamous intraepithelial lesions.

    Anal high-grade squamous intraepithelial lesionsBurkitt lymphomaCD19CD7
  13. Paper· Oral Oncol

    Investigating the impact of margins on the management of oropharyngeal cancer treated with transoral robotic surgery: a survey of head and neck oncologists' treatment patterns.

    Published in Oral Oncol on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

    Transoral robotic surgery
  14. Paper· Biochem Pharmacol

    IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

    Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for Acute promyelocytic leukaemia.

    Acute promyelocytic leukaemia
  15. Paper· Cancer Metastasis Rev

    Precision therapeutic strategies for advanced gastrointestinal stromal tumors.

    Published in Cancer Metastasis Rev on 19 September 2026; matched the OnCo record for Ripretinib.

    Ripretinib
  16. Paper· Transplant Cell Ther

    Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT.

    Published in Transplant Cell Ther on 19 September 2026; matched the OnCo record for CD33.

    CD33
  17. Paper· Clin Drug Investig

    Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.

    Published in Clin Drug Investig on 19 September 2026; matched the OnCo record for Bendamustine.

    Bendamustine
  18. Paper· Int J Surg Pathol

    Salivary Duct Carcinoma With Rhabdoid and Signet-Ring Cell Features Mimicking Invasive Lobular Carcinoma of the Breast: A Case Report and Review of the Literature.

    Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Salivary duct carcinoma.

    Salivary duct carcinoma
  19. Paper· Int J Hematol

    Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.

    Published in Int J Hematol on 19 September 2026; matched the OnCo record for Decitabine.

    DecitabineQuizartinib
  20. Paper· Target Oncol

    Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

    Published in Target Oncol on 19 September 2026; matched the OnCo record for Tucatinib.

    Tucatinib
  21. Paper· Int J Clin Oncol

    Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.

    Published in Int J Clin Oncol on 19 September 2026; matched the OnCo record for Amrubicin.

    Amrubicin
  22. Paper· J Robot Surg

    Transoral Robotic Surgery (TORS) versus radical radiotherapy following neoadjuvant therapy for oropharyngeal carcinoma: a multicenter, real-world efficacy and safety analysis.

    Published in J Robot Surg on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

    Transoral robotic surgery

60

  1. Paper· J Clin Oncol

    Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

    Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.

    Early-stage classical Hodgkin lymphoma
  2. Paper· Cancer Discov

    Phase III Trials Test First-Line Options in Advanced NSCLC.

    Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.

    AmivantamabIvonescimabZipalertinib
  3. Paper· Cancer Cell

    γδ T cells modulate anti-tumor immunity in small cell lung cancer.

    Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.

    Zoledronic acid
  4. Paper· Oncol Rep

    [Corrigendum] The interaction between miR‑148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer.

    Published in Oncol Rep on 18 September 2026; matched the OnCo record for DNMT1.

    DNMT1
  5. Paper· Dermatologie (Heidelb)

    [Update on anal dysplasia and anal cancer].

    Published in Dermatologie (Heidelb) on 18 September 2026; matched the OnCo record for Metastatic and recurrent anal squamous cell carcinoma.

    Metastatic and recurrent anal squamous cell carcinomaRetifanlimab
  6. Paper· Oncogene

    A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis.

    Published in Oncogene on 18 September 2026; matched the OnCo record for Genetically engineered mouse models.

    Genetically engineered mouse models
  7. Paper· Mol Med Rep

    A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.

    Published in Mol Med Rep on 18 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.

    EGFR-mutated non-small-cell lung cancer
  8. Paper· Br J Haematol

    A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

    Published in Br J Haematol on 18 September 2026; matched the OnCo record for Avelumab.

    Avelumab
  9. Paper· Clin Oncol (R Coll Radiol)

    Acute Myocardial Infarction in Head and Neck Cancer Patients and Survivors: A Population-Based Cohort Study of Patient, Disease, and Treatment Factors.

    Published in Clin Oncol (R Coll Radiol) on 18 September 2026; matched the OnCo record for Hypopharyngeal cancer.

    Hypopharyngeal cancer
  10. Paper· Mol Cell Proteomics

    Anagrelide remodels the PDE3A-SLFN12 interactome to associate with translation initiation machinery in cancer cell lines.

    Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Anagrelide.

    Anagrelide
  11. Paper· J Clin Pathol

    Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation.

    Published in J Clin Pathol on 18 September 2026; matched the OnCo record for Paige Prostate Detect.

    Paige Prostate Detect
  12. Paper· Spine J

    Beyond Anatomical Resectability: A Hypermetabolic and Highly Aggressive Subtype of Spinal Chordoma Associated with Cancer-Specific Progression.

    Published in Spine J on 18 September 2026; matched the OnCo record for Chordoma.

    Chordoma
  13. Paper· BMJ Open

    Can early <sup>68</sup>Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium.

    Published in BMJ Open on 18 September 2026; matched the OnCo record for Gallium-68 gozetotide.

    Gallium-68 gozetotide
  14. Paper· Angew Chem Int Ed Engl

    Carbohydrate-Directed Labeling Probes for UV-Independent Chemoproteomic Profiling of Carbohydrate-Protein Interactions.

    Published in Angew Chem Int Ed Engl on 18 September 2026; matched the OnCo record for CD22.

    CD22
  15. Paper· J Urol

    Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis.

    Published in J Urol on 18 September 2026; matched the OnCo record for Testicular germ cell tumours.

    Testicular germ cell tumours
  16. Paper· Cell Rep Med

    Class visualizations and activation atlases for computational pathology.

    Published in Cell Rep Med on 18 September 2026; matched the OnCo record for Pathology & radiology foundation models.

    Pathology & radiology foundation models
  17. Paper· Int J Surg Pathol

    Claudin 18.2 Expression and Outcomes in Resected Gallbladder and Biliary Tract Adenocarcinomas: A Pilot Clinicopathologic Study.

    Published in Int J Surg Pathol on 18 September 2026; matched the OnCo record for VENTANA PD-L1 (SP263) Assay.

    VENTANA PD-L1 (SP263) Assay
  18. Paper· Am J Clin Oncol

    Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor-Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

    Published in Am J Clin Oncol on 18 September 2026; matched the OnCo record for Rivoceranib.

    Rivoceranib
  19. Paper· Patient

    Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial.

    Published in Patient on 18 September 2026; matched the OnCo record for Vimseltinib.

    Vimseltinib
  20. Paper· J Am Acad Dermatol

    Community-Based Skin Cancer Screening and Follow-up Outcomes from a Statewide Outreach Program.

    Published in J Am Acad Dermatol on 18 September 2026; matched the OnCo record for Skin cancer screening.

    Skin cancer screening
  21. Paper· Cancer Res Commun

    Compartment-specific CD8 infiltration and disease-specific survival in resected ampullary adenocarcinoma.

    Published in Cancer Res Commun on 18 September 2026; matched the OnCo record for Ampullary cancer.

    Ampullary cancer
  22. Paper· BMJ Case Rep

    Disseminated <i>Fusarium</i> infection following cladribine chemotherapy for hairy-cell leukaemia.

    Published in BMJ Case Rep on 18 September 2026; matched the OnCo record for Cladribine.

    CladribineHairy cell leukaemia
  23. Paper· Ann Med

    Effect of transcutaneous auricular vagus nerve stimulation on postoperative gastrointestinal dysfunction in patients with gynecological abdominal or pelvic tumors: a study protocol for a prospective, single-center, randomized, controlled clinical trial.

    Published in Ann Med on 18 September 2026; matched the OnCo record for Stage III melanoma.

    Stage III melanoma
  24. Paper· Urol Oncol

    Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.

    Published in Urol Oncol on 18 September 2026; matched the OnCo record for Gemcitabine + cisplatin.

    Gemcitabine + cisplatinToripalimab
  25. Paper· J Neurooncol

    Efficacy and safety of proton radiotherapy for progressive or surgically unfavorable adult pilocytic astrocytoma: a single-center experience.

    Published in J Neurooncol on 18 September 2026; matched the OnCo record for Paediatric low-grade glioma.

    Paediatric low-grade glioma
  26. Paper· Curr Opin Oncol

    Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma.

    Published in Curr Opin Oncol on 18 September 2026; matched the OnCo record for Vorasidenib.

    Vorasidenib
  27. Paper· Actas Dermosifiliogr

    Erythematous dorsal plaques in 6 patients with advanced T-cell lymphoma: a clinical variant of mogamulizumab-associated rash.

    Published in Actas Dermosifiliogr on 18 September 2026; matched the OnCo record for Mogamulizumab.

    Mogamulizumab
  28. Paper· BMC Med Imaging

    FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer.

    Published in BMC Med Imaging on 18 September 2026; matched the OnCo record for Locally advanced cervical cancer.

    Locally advanced cervical cancerRecurrent or metastatic cervical cancer
  29. Paper· Phys Med

    Feasibility of prostate offline adaptive radiation therapy using iterative reconstructed CBCT to optimize the ART workflow.

    Published in Phys Med on 18 September 2026; matched the OnCo record for MR-guided adaptive radiotherapy.

    MR-guided adaptive radiotherapy
  30. Paper· J Immunother Cancer

    Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy.

    Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Imaging mass cytometry.

    Imaging mass cytometry
  31. Paper· J Immunother Cancer

    Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.

    Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Ciltacabtagene autoleucel.

    Ciltacabtagene autoleucelIdecabtagene vicleucel
  32. Paper· J Comp Eff Res

    Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome.

    Published in J Comp Eff Res on 18 September 2026; matched the OnCo record for Small intestine cancer.

    Small intestine cancer
  33. Paper· Blood Adv

    Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

    Published in Blood Adv on 18 September 2026; matched the OnCo record for Allogeneic stem cell transplantation.

    Allogeneic stem cell transplantationLoncastuximab tesirine
  34. Paper· Future Oncol

    MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

    Published in Future Oncol on 18 September 2026; matched the OnCo record for Node-positive and metastatic penile cancer.

    Node-positive and metastatic penile cancerPucotenlimab
  35. Paper· Structure

    Modulating pseudokinase conformation from the ATP-binding site.

    Published in Structure on 18 September 2026; matched the OnCo record for HER3.

    HER3
  36. Paper· Curr Hematol Malig Rep

    Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026.

    Published in Curr Hematol Malig Rep on 18 September 2026; matched the OnCo record for Ropeginterferon alfa-2b.

    Ropeginterferon alfa-2b
  37. Paper· Auris Nasus Larynx

    Molecular targeted therapy for thyroid cancer in Japan: Current status and future perspectives.

    Published in Auris Nasus Larynx on 18 September 2026; matched the OnCo record for Companion diagnostics.

    Companion diagnostics
  38. Paper· J Comput Assist Tomogr

    Multiparametric Whole-Body MRI Protocols in Contemporary Clinical Practice: Indications, Technical Considerations, and Emerging Applications.

    Published in J Comput Assist Tomogr on 18 September 2026; matched the OnCo record for Whole-body MRI.

    Whole-body MRI
  39. Paper· Mol Biol Rep

    NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models.

    Published in Mol Biol Rep on 18 September 2026; matched the OnCo record for CRAF.

    CRAF
  40. Paper· Drug Resist Updat

    Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway.

    Published in Drug Resist Updat on 18 September 2026; matched the OnCo record for Pazopanib.

    Pazopanib
  41. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-18

    303 changelog entries, 1 upcoming date, 11 publications, 8 corrections.

  42. Paper· Asian J Androl

    Onvansertib-mediated PLK1 inhibition impairs spermatogenesis in the murine testis.

    Published in Asian J Androl on 18 September 2026; matched the OnCo record for Onvansertib.

    Onvansertib
  43. Paper· ACS Sens

    Optimizing the Hinge Length of Chimeric Antigen Receptor with a DdFP-Based Immunological Synapse Biosensor.

    Published in ACS Sens on 18 September 2026; matched the OnCo record for Mesothelin.

    Mesothelin
  44. Paper· Oncol Rep

    Pemetrexed increases BRCA1 protein stability and sensitizes TNBC cells to radiotherapy.

    Published in Oncol Rep on 18 September 2026; matched the OnCo record for Pemetrexed.

    Pemetrexed
  45. Paper· J Enzyme Inhib Med Chem

    Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential.

    Published in J Enzyme Inhib Med Chem on 18 September 2026; matched the OnCo record for PARP.

    PARP
  46. Paper· Cancer Lett

    Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.

    Published in Cancer Lett on 18 September 2026; matched the OnCo record for cfDNA fragmentomics.

    cfDNA fragmentomics
  47. Paper· Diagnosis (Berl)

    Plasma signals of lung tumor promotion and the ubiquitous challenge of biomarker specificity.

    Published in Diagnosis (Berl) on 18 September 2026; matched the OnCo record for CEACAM5.

    CEACAM5
  48. Paper· Mol Cell Proteomics

    PRC2 loss in MPNST is accompanied by SWI/SNF complex rewiring and sensitization to SMARCA2/4 and BET inhibition in vivo.

    Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Malignant peripheral nerve sheath tumour.

    Malignant peripheral nerve sheath tumour
  49. Paper· J Formos Med Assoc

    Pre-operative magnetic resonance imaging for evaluating depth of invasion in oral tongue cancer: Precision and predictive value.

    Published in J Formos Med Assoc on 18 September 2026; matched the OnCo record for Oral tongue and floor of mouth cancer.

    Oral tongue and floor of mouth cancer
  50. Paper· J Geriatr Oncol

    Prognostic value of the Nice Cancer Ageing Survival (NCAS) score in older adults with cancer: A retrospective single institutional study.

    Published in J Geriatr Oncol on 18 September 2026; matched the OnCo record for Geriatric assessment.

    Geriatric assessment
  51. Paper· Ann Surg Oncol

    Recurrence Patterns of Resected Ampullary Adenocarcinoma and Implications for Multimodal Therapy: A Hidden Genome-Derived Analysis from the Ampullary Cancer Collaborative.

    Published in Ann Surg Oncol on 18 September 2026; matched the OnCo record for Ampullary cancer.

    Ampullary cancer
  52. Paper· Mol Genet Genomics

    Retraction Note: Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells.

    Published in Mol Genet Genomics on 18 September 2026; matched the OnCo record for Elongation factor 2.

    Elongation factor 2
  53. Paper· Biochim Biophys Acta Gen Subj

    Retraction notice to "Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth" [Biochim. Biophys. Acta (BBA) - Gen. Subj. 1860 (2016) 1961-1972].

    Published in Biochim Biophys Acta Gen Subj on 18 September 2026; matched the OnCo record for Smoothened.

    Smoothened
  54. Paper· Curr Probl Cancer

    Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

    Published in Curr Probl Cancer on 18 September 2026; matched the OnCo record for Teclistamab.

    Teclistamab
  55. Paper· Mol Cancer Ther

    Systematic Evaluation of Combination Strategies with Rezatapopt in p53 Y220C-Mutant Cancer Models.

    Published in Mol Cancer Ther on 18 September 2026; matched the OnCo record for MDM2 inhibitors.

    MDM2 inhibitors
  56. Paper· J Natl Compr Canc Netw

    Targeting KRAS-Mutant Lung Cancers.

    Published in J Natl Compr Canc Netw on 18 September 2026; matched the OnCo record for Adagrasib.

    AdagrasibDaraxonrasibKRAS G12C-mutant non-small-cell lung cancerSotorasibZoldonrasib
  57. Paper· Bioorg Chem

    Targeting overexpressed tumor cell receptors with radiolabeled molecules: Biological targets, clinical applications, and translational challenges.

    Published in Bioorg Chem on 18 September 2026; matched the OnCo record for Somatostatin receptor 2.

    Somatostatin receptor 2
  58. Paper· J Cancer Res Clin Oncol

    Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort.

    Published in J Cancer Res Clin Oncol on 18 September 2026; matched the OnCo record for Synovial sarcoma.

    Synovial sarcoma
  59. Paper· Brain Stimul

    Vagus Nerve Stimulation Exerts Disease-Modifying Effects in Epileptic Rats by Enhancing Hippocampal Adenosine Signalling.

    Published in Brain Stimul on 18 September 2026; matched the OnCo record for Pilocarpine.

    Pilocarpine
  60. Paper· Oncol Rep

    Validation of next‑generation sequencing‑derived circulating mRNA variants as potential diagnostic tools in hepatocellular carcinoma and cholangiocarcinoma.

    Published in Oncol Rep on 18 September 2026; matched the OnCo record for Interferon alfa-2a/2b.

    Interferon alfa-2a/2b

29

  1. Paper· Science

    An expert-level generalist AI for abdominal CT diagnosis.

    Published in Science on 17 September 2026; matched the OnCo record for RaDaR.

    RaDaR
  2. Paper· Cancer Discov

    Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

    Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.

    YL201
  3. Paper· Nat Med

    Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.

    Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

    Diffuse midline glioma, H3 K27-altered
  4. Paper· Ann Oncol

    Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

    Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.

    Goserelin / leuprolide
  5. Paper· Bull Cancer

    [Tenosyovial giant cell tumor (TGCT): From the physiopathology to the emergence of new targeted therapies].

    Published in Bull Cancer on 17 September 2026; matched the OnCo record for Tenosynovial giant cell tumour.

    Tenosynovial giant cell tumour
  6. Paper· Hemasphere

    A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

    Published in Hemasphere on 17 September 2026; matched the OnCo record for Functional (ex vivo) drug testing.

    Functional (ex vivo) drug testing
  7. Paper· Mod Pathol

    Acute Myeloid Leukemia With KMT2A Amplification: A TP53-Alteration-Enriched Subgroup Associated With Chromoanagenesis and Poor Prognosis.

    Published in Mod Pathol on 17 September 2026; matched the OnCo record for Secondary and therapy-related acute myeloid leukaemia.

    Secondary and therapy-related acute myeloid leukaemia
  8. Paper· Ann Med

    Admission low-density lipoprotein cholesterol and early haematoma expansion after spontaneous intracerebral haemorrhage.

    Published in Ann Med on 17 September 2026; matched the OnCo record for CT.

    CT
  9. Paper· Pulmonology

    ALPHA-1 antitrypsin genotype, sex, and lung cancer: Clinical and molecular characterisation.

    Published in Pulmonology on 17 September 2026; matched the OnCo record for EGFR.

    EGFR
  10. Paper· Signal Transduct Target Ther

    An integrated multiomic single-vesicle atlas delineates graft exosome heterogeneity in chronic lung allograft dysfunction.

    Published in Signal Transduct Target Ther on 17 September 2026; matched the OnCo record for CD73 / adenosine axis.

    CD73 / adenosine axisG-CSF receptor
  11. Paper· Orthop Surg

    Artificial Intelligence-Driven Precision Bisphosphonate Therapy in Osteoporosis: Mechanisms, Clinical Applications, Risks, and Future Directions.

    Published in Orthop Surg on 17 September 2026; matched the OnCo record for Zoledronic acid.

    Zoledronic acid
  12. Paper· Ann Med

    Association of body mass index with postoperative pulmonary complications and potential explanatory pathways in paediatric scoliosis correction surgery: a multicentre cohort study.

    Published in Ann Med on 17 September 2026; matched the OnCo record for Neuroblastoma.

    Neuroblastoma
  13. Paper· Ann Med

    Biochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia.

    Published in Ann Med on 17 September 2026; matched the OnCo record for EGFR.

    EGFR
  14. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-17

    147 changelog entries, 1 upcoming date, 14 publications, 91 corrections.

  15. Proposal· FDA

    Proposed approval: Givinostat

    openFDA has a label for "Givinostat".

    Givinostat
  16. Proposal· EMA

    Proposed regional approval row: Alemtuzumab

    EMA register: MabCampath (alemtuzumab) Withdrawn, 2001-07-06.

    Alemtuzumab
  17. Proposal· EMA

    Proposed regional approval row: Anagrelide

    EMA register: Xagrid (anagrelide) Authorised, 2004-11-15.

    Anagrelide
  18. Proposal· EMA

    Proposed regional approval row: Aprepitant

    EMA register: Emend (aprepitant) Authorised, 2003-11-11.

    Aprepitant
  19. Proposal· EMA

    Proposed regional approval row: Bexarotene

    EMA register: Targretin (bexarotene) Authorised, 2001-03-29.

    Bexarotene
  20. Proposal· EMA

    Proposed regional approval row: Busulfan

    EMA register: Busilvex (busulfan) Withdrawn, 2003-07-09.

    Busulfan
  21. Proposal· EMA

    Proposed regional approval row: Capecitabine

    EMA register: Xeloda (capecitabine) Authorised, 2001-02-02.

    Capecitabine
  22. Proposal· EMA

    Proposed regional approval row: Capmatinib

    EMA register: Tabrecta (capmatinib) Authorised, 2022-06-20.

    Capmatinib
  23. Proposal· EMA

    Proposed regional approval row: Carmustine

    EMA register: Carmustine medac (previously Carmustine Obvius) (carmustine) Authorised, 2018-07-18.

    Carmustine
  24. Proposal· EMA

    Proposed regional approval row: Catumaxomab

    EMA register: Korjuny (catumaxomab) Authorised, 2025-02-10.

    Catumaxomab
  25. Proposal· EMA

    Proposed regional approval row: Clofarabine

    EMA register: Evoltra (clofarabine) Authorised, 2006-05-29.

    Clofarabine
  26. Proposal· EMA

    Proposed regional approval row: Cytarabine

    EMA register: DepoCyte (cytarabine) Withdrawn, 2001-07-11.

    Cytarabine
  27. Proposal· EMA

    Proposed regional approval row: Dabrafenib

    EMA register: Tafinlar (dabrafenib) Authorised, 2013-08-26.

    Dabrafenib
  28. Proposal· EMA

    Proposed regional approval row: Darbepoetin alfa

    EMA register: Aranesp (darbepoetin alfa) Authorised, 2001-06-08.

    Darbepoetin alfa
  29. Proposal· EMA

    Proposed regional approval row: Daunorubicin

    EMA register: Vyxeos liposomal (previously Vyxeos) (daunorubicin;cytarabine) Authorised, 2018-08-23.

    Daunorubicin

4

  1. Paper· J Clin Oncol

    Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA-Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer.

    Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Localised anal squamous cell carcinoma.

    Localised anal squamous cell carcinoma
  2. Paper· Cancer Cell

    Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

    Published in Cancer Cell on 16 September 2026; matched the OnCo record for Adebrelimab.

    Adebrelimab
  3. Paper· J Clin Oncol

    Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

    Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Trastuzumab rezetecan.

    Trastuzumab rezetecan
  4. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-16

    17 changelog entries, 1 upcoming date, 20 publications, 89 corrections.

18

  1. Paper· Nature

    Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance.

    Published in Nature on 15 September 2026; matched the OnCo record for Erythropoietin receptor.

    Erythropoietin receptor
  2. Paper· Nat Med

    Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS<sup>G12D</sup> mutations: a phase 1 trial.

    Published in Nat Med on 15 September 2026; matched the OnCo record for GFH375.

    GFH375
  3. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-15

    14 changelog entries, 1 upcoming date, 20 publications, 89 corrections.

  4. Preprint· bioRxiv

    Accurate and scalable decontamination of imaging-based spatial transcriptomics via optimal transport

    Posted on bioRxiv on 15 September 2026; not peer reviewed; matched Single-cell & spatial profiling and Spatial transcriptomics.

    Single-cell & spatial profilingSpatial transcriptomics
  5. Preprint· Research Square

    An outcome-blind H&E architecture score is associated with prostate cancer-specific mortality

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Pathology & radiology foundation models and Prov-GigaPath.

    Pathology & radiology foundation modelsProv-GigaPath
  6. Preprint· bioRxiv

    An Oxidative Stress-Associated Seven-Gene Prognostic Signature in Lung Adenocarcinoma: Integrative Transcriptomic Analysis Across Public Cohorts

    Posted on bioRxiv on 15 September 2026; not peer reviewed; matched AKT and Atlas.

    AKTAtlas
  7. Preprint· Research Square

    CD163 Expression as an Independent Prognostic Biomarker in Glioblastoma: A Digital Pathology and Survival Analysis Study

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Histopathology & immunohistochemistry and Iobenguane I-131.

    Histopathology & immunohistochemistryIobenguane I-131
  8. Preprint· Research Square

    Construct validity and evidence boundaries of a 17-gene transcriptomic proxy for mitoxyperilysis in colorectal aging and cancer Analysis

    Posted on Research Square on 15 September 2026; not peer reviewed; matched MET.

    MET
  9. Preprint· Research Square

    Context-dependent rewiring of autocrine TGFβ/RhoA/ROCK1 under complete vs deprived serum conditions in TNBC transduced cells

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Iobenguane I-131.

    Iobenguane I-131
  10. Preprint· Research Square

    Cost-effectiveness and carbon footprint of cystoscopic surveillance schedules in non-muscle-invasive bladder cancer

    Posted on Research Square on 15 September 2026; not peer reviewed; matched State.

    State
  11. Preprint· Research Square

    Cranial Radiotherapy Combined with Afatinib in Non-Small Cell Lung Cancer Patients with EGFR G719X+S768I Co-Mutations and Brain Metastases: A Retrospective Study

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Nintedanib, EGFR and Afatinib.

    NintedanibEGFRAfatinibIobenguane I-131
  12. Preprint· Research Square

    Cross-cohort evaluation of thyroid ultrasound deep learning across different outcome definitions: a duplicate-controlled benchmark

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Ultrasound.

    Ultrasound
  13. Preprint· medRxiv

    Cross-Source Progression Assessment in Advanced Pancreatic Cancer: An Opportunity-Adjusted Six-State Analysis

    Posted on medRxiv on 15 September 2026; not peer reviewed; matched State.

    State
  14. Preprint· Research Square

    DFT-based prediction of anti-cancer activity of some organo-Pt IV complexes

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Cisplatin, Platinum agents and Carboplatin.

    CisplatinPlatinum agentsCarboplatinOxaliplatin
  15. Preprint· Preprints.org

    Drug–Drug Interactions in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated with Immunotherapy: A Multicenter Cohort Study

    Posted on Preprints.org on 15 September 2026; not peer reviewed; matched Immune checkpoint inhibitors, Pembrolizumab and Nivolumab.

    Immune checkpoint inhibitorsPembrolizumabNivolumab
  16. Preprint· Research Square

    Evaluating Patient Satisfaction with Oncology Pharmacy Services in Regional Referral Centers: A Mixed-Methods Approach

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Iobenguane I-131.

    Iobenguane I-131
  17. Preprint· Research Square

    Evaluation of CBCT-based HU correction for synthetic CT generation in head-and-neck radiotherapy: FOV-stratified and peripheral-region analysis

    Posted on Research Square on 15 September 2026; not peer reviewed; matched IMRT / IGRT.

    IMRT / IGRT
  18. Preprint· Research Square

    Germline pharmacogenomic predictors of treatment-related toxicity in non-small cell lung cancer: a systematic review of the discovery-to-implementation gap

    Posted on Research Square on 15 September 2026; not peer reviewed; matched Nintedanib, PD-1 and KRAS.

    NintedanibPD-1KRASTP53

2

  1. Paper· Nat Cancer

    Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

    Published in Nat Cancer on 14 September 2026; matched the OnCo record for FOLFIRI.

    FOLFIRI
  2. Paper· J Clin Oncol

    P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in <i>EGFR</i>-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

    Published in J Clin Oncol on 14 September 2026; matched the OnCo record for Afatinib.

    AfatinibAmivantamabSunvozertinibZipalertinib

1

  1. Paper· N Engl J Med

    Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

    Published in N Engl J Med on 12 September 2026; matched the OnCo record for YL201.

    YL201

2

  1. Paper· Ann Oncol

    Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

    Published in Ann Oncol on 11 September 2026; matched the OnCo record for Bispecific ADC.

    Bispecific ADCIzalontamab brengitecan
  2. Paper· J Clin Oncol

    Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

    Published in J Clin Oncol on 11 September 2026; matched the OnCo record for HER2 tyrosine kinase inhibitors.

    HER2 tyrosine kinase inhibitorsTrastuzumab emtansine

1

  1. Approval· FDA

    FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

    On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

    SevabertinibNon-small-cell lung cancerHER2-mutant non-small-cell lung cancerHER2

2

  1. Approval· FDA

    Approval: Camizestrant (US)

    Accelerated approval (Etcamah).

    CamizestrantHR-positive / HER2-negative breast cancerHR-positive metastatic breast cancer after CDK4/6 inhibitorsEstrogen receptor
  2. Approval· FDA

    FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

    On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

    CamizestrantPalbociclibAbemaciclibRibociclibHR-positive / HER2-negative breast cancer

2

  1. Approval· FDA

    Approval: Daraxonrasib (US)

    NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

    DaraxonrasibPancreatic ductal adenocarcinomaMetastatic pancreatic ductal adenocarcinomaKRAS G12C-mutant pancreatic ductal adenocarcinomaNon-small-cell lung cancerColorectal cancer
  2. Approval· FDA

    FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

    On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

    Daraxonrasib

1

  1. Approval· FDA

    FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma

    On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.

    TislelizumabZanidatamabPlatinum + etoposideGastric & gastro-oesophageal junction cancerOesophageal cancerNon-small-cell lung cancerHepatocellular carcinomaRecurrent and metastatic nasopharyngeal carcinomaBiliary tract cancerHER2

1

  1. Approval· FDA

    FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

    On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

    DexamethasoneDaratumumabIberdomideMultiple myelomaSmouldering multiple myelomaNewly diagnosed multiple myeloma, transplant-eligibleNewly diagnosed multiple myeloma, transplant-ineligiblePlasma cell leukaemiaAcute lymphoblastic leukaemiaDiffuse large B-cell lymphomaHodgkin lymphoma

1

  1. Approval· FDA

    FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

    On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

    Vusolimogene oderparepvecNivolumabRelatlimab + nivolumabMelanomaNon-small-cell lung cancerRenal cell carcinomaHodgkin lymphomaColorectal cancer

2

  1. Approval· FDA

    Approval: Amivantamab (US)

    Subcutaneous formulation (PALOMA-3).

    AmivantamabNon-small-cell lung cancerEGFR-mutated non-small-cell lung cancerMET exon 14 and MET-amplified non-small-cell lung cancerEGFRMETArteraAI BreastHR-positive / HER2-negative breast cancerAtezolizumabSmall-cell lung cancerHepatocellular carcinomaAdvanced hepatocellular carcinomaBladder & urothelial cancerBelantamab mafodotinMultiple myelomaRelapsed or refractory multiple myelomaBCMACemiplimabMelanomaPD-L1-high non-small-cell lung cancer without a driver mutationCutaneous squamous cell carcinomaAdvanced cutaneous squamous cell carcinomaDurvalumabBiliary tract cancerIntrahepatic cholangiocarcinomaExtrahepatic cholangiocarcinomaEncorafenibColorectal cancerBRAF V600E-mutant colorectal cancerBRAF V600E-mutant non-small-cell lung cancerLutetium-177 vipivotide tetraxetanProstate cancerMetastatic castration-resistant prostate cancerMetastatic hormone-sensitive prostate cancerPSMANivolumabRenal cell carcinomaHodgkin lymphomaOptune / Optune PaxGlioma & glioblastomaPancreatic ductal adenocarcinomaLocally advanced unresectable pancreatic ductal adenocarcinomaMesotheliomaPembrolizumabMismatch repair deficient (MSI-high) pancreatic ductal adenocarcinomaTriple-negative breast cancerHead and neck squamous cell carcinomaPiflufolastat F-18 / Pylarify TruVuRelacorilantOvarian cancerPlatinum-resistant ovarian cancerAdvanced and metastatic adrenocortical carcinomaRevumenibAcute myeloid leukaemiaAcute lymphoblastic leukaemiaNPM1-mutated and KMT2A-rearranged acute myeloid leukaemiaMeninSatricabtagene autoleucelGastric & gastro-oesophageal junction cancerClaudin 18.2TarlatamabExtensive-stage small-cell lung cancerLimited-stage small-cell lung cancerDLL3CD3TeclistamabTrastuzumab deruxtecanHER2-positive breast cancerHER2-positive gastric cancerVepdegestrantHR-positive metastatic breast cancer after CDK4/6 inhibitorsEstrogen receptorVusolimogene oderparepvecAdvanced melanomaZenocutuzumabKRAS wild-type pancreatic ductal adenocarcinomaHER2ZongertinibHER2-mutant non-small-cell lung cancer
  2. Approval· FDA

    FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).

    Lutetium-177 vipivotide tetraxetanProstate cancer

1

  1. Approval· FDA

    FDA approves zidesamtinib for ROS1 -positive non-small cell lung cancer

    On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

    ZidesamtinibNon-small-cell lung cancerROS1-positive non-small-cell lung cancer

2

  1. Approval· FDA

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

    FulvestrantPalbociclibGedatolisibHR-positive / HER2-negative breast cancerEstrogen receptorHR-positive metastatic breast cancer after CDK4/6 inhibitorsPIK3CA / PI3K-alphaAKTHER2-positive breast cancerCDK4/6
  2. Approval· FDA

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

    SelpercatinibThyroid cancerNon-small-cell lung cancerMedullary thyroid cancerPapillary thyroid cancerRET fusion-positive non-small-cell lung cancer

1

  1. Approval· FDA

    FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC).

    Enfortumab vedotinPembrolizumabGemcitabine + cisplatinCisplatinBladder & urothelial cancerMuscle-invasive and advanced bladder cancerNectin-4Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinomaTriple-negative breast cancerNon-small-cell lung cancerMelanomaHead and neck squamous cell carcinoma

1

  1. Approval· FDA

    FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

    On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S.

    IsatuximabMultiple myelomaNewly diagnosed multiple myeloma, transplant-ineligibleCD38

1

  1. Withdrawal· FDA

    Withdrawal: Zelenectide pevedotin (US)

    Programme deprioritised after regulatory feedback on Duravelo-2 design.

    Zelenectide pevedotinBladder & urothelial cancerNectin-4

16

  1. Result· onclive.com

    BL-B01D1-307: Phase 3 result

    PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).

    BL-B01D1-307Izalontamab brengitecanTriple-negative breast cancer
  2. Result· cancernetwork.com

    CLARITY-Gastric 01: Phase 3 result

    Co-primary endpoints including OS met (July 2026); numbers pending.

    CLARITY-Gastric 01Sonesitatug vedotinRamucirumabGastric & gastro-oesophageal junction cancerClaudin 18.2
  3. Result· amgen.com

    DeLLphi-305: Phase 3 result

    Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.

    DeLLphi-305TarlatamabDurvalumabSmall-cell lung cancerExtensive-stage small-cell lung cancerDLL3
  4. Result· ClinicalTrials.gov

    DREAM3R: Phase 3 result

    Stopped early; primary endpoint not met.

    DREAM3RDurvalumabPemetrexedMesothelioma
  5. Result· astrazeneca.com

    EMERALD-3: Phase 3 result

    PFS HR ~0.70 (interim); OS immature.

    EMERALD-3DurvalumabTremelimumabLenvatinibHepatocellular carcinomaIntermediate hepatocellular carcinoma
  6. Result· ir.genmab.com

    EPCORE DLBCL-1: Phase 3 result

    PFS HR 0.74; OS HR 0.96 (NS).

    EPCORE DLBCL-1EpcoritamabDiffuse large B-cell lymphoma
  7. Withdrawal· European Commission (EMA opinion)

    EU withdrawal: Duvelisib

    Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).

    DuvelisibChronic lymphocytic leukaemiaPeripheral T-cell lymphomasPIK3CA / PI3K-alpha
  8. Result· cancernetwork.com

    Fianlimab + cemiplimab phase 3: Phase 3 result

    Primary PFS endpoint not met; numerical +5.1 months median PFS at the high dose.

    Fianlimab + cemiplimab phase 3FianlimabCemiplimabPembrolizumabMelanomaAdvanced melanoma
  9. Result· DOI

    FIGHT-302: Phase 3 result

    Progression-free survival: Pemigatinib 8.3 months versus Gemcitabine + cisplatin 6.8 months, hazard ratio 0.58.

    FIGHT-302PemigatinibGemcitabine + cisplatinBiliary tract cancerIntrahepatic cholangiocarcinomaBiliary tract cancer
  10. Result· ClinicalTrials.gov

    HARMONi-3: Phase 3 result

    Interim PFS not statistically significant (May 2026); final readouts pending.

    HARMONi-3IvonescimabPembrolizumabNon-small-cell lung cancerPD-L1-high non-small-cell lung cancer without a driver mutation
  11. Result· ASCO journals

    HERIZON-GEA-01: Phase 3 result

    PFS 12.4 vs 8.1 months (HR 0.63-0.65); OS significantly improved.

    HERIZON-GEA-01ZanidatamabTrastuzumabTislelizumabGastric & gastro-oesophageal junction cancerOesophageal cancer
  12. Result· merck.com

    INTerpath-001: Phase 3 result

    RFS and DMFS significantly improved (HRs pending presentation).

    INTerpath-001Intismeran autogenePembrolizumabMelanomaStage III melanomaStage IIB and IIC melanoma
  13. Result· ClinicalTrials.gov

    Krascendo 1: Phase 3 result

    Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).

    Krascendo 1DivarasibSotorasibAdagrasibNon-small-cell lung cancerKRAS G12C-mutant non-small-cell lung cancer
  14. Result· merck.com

    LITESPARK-012: Phase 3 result

    Primary endpoint not met (ASCO GU 2026).

    LITESPARK-012BelzutifanLenvatinibPembrolizumabRenal cell carcinoma
  15. Result· NEJM

    LITESPARK-022: Phase 3 result

    DFS significantly improved vs pembrolizumab (interim; HR presented ASCO GU 2026).

    LITESPARK-022BelzutifanPembrolizumabRenal cell carcinomaHIF-2α
  16. Result· DOI

    MATRix/IELSG43: Phase 3 result

    Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.43, p 0.0003), with better overall survival and more toxicity.

    MATRix/IELSG43ThiotepaCarmustineRituximabMethotrexateCytarabine

2

  1. Withdrawal· European Commission (EMA opinion)

    EU withdrawal: Lifileucel

    Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).

    LifileucelMelanomaNon-small-cell lung cancerAdvanced melanoma
  2. Law· European Union, regulation

    European Health Data Space Regulation (EU) 2025/327

    A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.

    European Health Data Space Regulation (EU) 2025/327GDPR and health dataOncology EHR and real-world data platformsReal-world evidence

Sources

Everything above is read at build time from snapshots and records already in the repository; nothing is fetched when the page is viewed. Where each kind comes from and how often its source refreshes, from the workflow schedules in .github/workflows:

  • Approvals

    FDA Oncology Center of Excellence approval notifications (public/fda/recent.json), dated approvals recorded on product pages, and European Commission authorisations from the regional approvals table with an EPAR or regulator link.

    Refresh: FDA feed Wednesdays 06:07 UTC (refresh-fda.yml); EU rows checked against the EMA register Wednesdays 06:37 UTC (refresh-regional.yml); product pages by hand.

  • Withdrawals

    Dated withdrawals recorded on product pages and withdrawn EU authorisations in the regional approvals table, each with a source link.

    Refresh: Same schedule as approvals.

  • Results

    Trials in the corpus with a reported year and structured outcomes, linked to the primary paper, sponsor release or registry entry the outcome cites.

    Refresh: Curated by hand; ClinicalTrials.gov status refreshed Mondays 06:17 UTC (refresh-trials.yml).

  • Papers

    The newest Europe PMC matches for every product, target, cancer and technology (public/papers), journal versions of tracked preprints, and papers the roadmap watch found for landmark trials. One entry per DOI, however many records it matched.

    Refresh: Literature snapshot Tuesdays 05:41 UTC (refresh-papers.yml); roadmap watch Thursdays 05:29 UTC (roadmap-watch.yml).

  • Preprints

    bioRxiv, medRxiv, Research Square and other preprints of the last 90 days that match a target, product or technology query (public/preprints). Not peer reviewed.

    Refresh: Wednesdays 06:17 UTC (refresh-preprints.yml).

  • Law & policy

    Statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made, each linked to its primary text.

    Refresh: Curated by hand; new instruments are added when they are enacted.

  • Proposals

    Changes the nightly bot proposes for the corpus from the FDA feed, the EMA register and registry status changes (public/proposals/latest.json). Proposals, not facts: each waits for a human to apply it.

    Refresh: Daily 03:23 UTC (propose.yml).

  • Weekly issues

    OnCo's own weekly issue: what changed, regulatory events, upcoming readouts and what the journals published.

    Refresh: Mondays 07:31 UTC (newsletter.yml); the archive is rebuilt with every deploy.

Dates are shown at the precision the source gives: a year-only law or authorisation is grouped under its year, never given a day. Papers are matched to records by their literature queries, so a code or a common word can pull in an unrelated paper; the record chips tell you what matched. Not medical advice.